Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980528064> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2980528064 endingPage "257" @default.
- W2980528064 startingPage "252" @default.
- W2980528064 abstract "Epilepsy, an ancient disease, is defined as an enduring predisposition to generate epileptic seizures and by the neurobiological, cognitive, psychological, and social consequences of this condition. Antiepileptic drugs (AEDs) are currently used as first-line treatment for patients with epilepsy; however, around 36% of patients are diagnosed with refractory epilepsy, which means two or more AEDs have been considered as failed after sufficiently correct usage. Unfortunately, it is unlikely that the improvement of the efficacy of AEDs will be easily achieved, especially since no AEDs show efficacy in ceasing epileptogenesis. Consequently, several endogenous anticonvulsants attract investigators and epileptologists, such as galanin, cannabis, and adenosine. Astrogliosis is a neuropathological hallmark of epilepsy, whatever the etiology is, and astrogliosis is frequently associated with overexpression of adenosine kinase, which means downregulation of synaptic levels of adenosine. Consequently, adenosine is negatively regulated by adenosine kinase through the astrocyte-based cycle. On the other hand, focal adenosine augmentation therapy, using adenosine kinase inhibitor, has been proved to be effective for reducing seizures in both animal models and in vitro human brain tissue resected from a variety of etiology of refractory epilepsy patients. In addition to reducing seizures, adenosine augmentation therapy can also palliate co-morbidities, like sleep, cognition, or depression. Of importance, transgenic mice with reduced ADK were resistant to epileptogenesis induced by acute brain injury. In terms of translation, based on findings of adenosinerelated epileptogenic mechanisms, the application into clinical practice seems to be feasible by molecular strategies that have been already experimentally implemented, including gene and RNA interference. In the present review, we will focus on the evidence of ADK dysfunction in the epileptic brain from human beings and animals, and review the role of ADK inhibitor in adenosine augmentation therapy and the underlying mechanism of prevention of epileptogenesis." @default.
- W2980528064 created "2019-10-25" @default.
- W2980528064 creator A5000345697 @default.
- W2980528064 creator A5021491888 @default.
- W2980528064 date "2020-02-21" @default.
- W2980528064 modified "2023-10-06" @default.
- W2980528064 title "Role of Adenosine Kinase Inhibitor in Adenosine Augmentation Therapy for Epilepsy: A Potential Novel Drug for Epilepsy" @default.
- W2980528064 doi "https://doi.org/10.2174/1389450119666191014104347" @default.
- W2980528064 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31633474" @default.
- W2980528064 hasPublicationYear "2020" @default.
- W2980528064 type Work @default.
- W2980528064 sameAs 2980528064 @default.
- W2980528064 citedByCount "9" @default.
- W2980528064 countsByYear W29805280642020 @default.
- W2980528064 countsByYear W29805280642021 @default.
- W2980528064 countsByYear W29805280642022 @default.
- W2980528064 countsByYear W29805280642023 @default.
- W2980528064 crossrefType "journal-article" @default.
- W2980528064 hasAuthorship W2980528064A5000345697 @default.
- W2980528064 hasAuthorship W2980528064A5021491888 @default.
- W2980528064 hasConcept C118552586 @default.
- W2980528064 hasConcept C126322002 @default.
- W2980528064 hasConcept C15744967 @default.
- W2980528064 hasConcept C169760540 @default.
- W2980528064 hasConcept C2776991684 @default.
- W2980528064 hasConcept C2777332695 @default.
- W2980528064 hasConcept C2778186239 @default.
- W2980528064 hasConcept C2779965356 @default.
- W2980528064 hasConcept C2780876210 @default.
- W2980528064 hasConcept C34628245 @default.
- W2980528064 hasConcept C529278444 @default.
- W2980528064 hasConcept C57236427 @default.
- W2980528064 hasConcept C71924100 @default.
- W2980528064 hasConcept C98274493 @default.
- W2980528064 hasConceptScore W2980528064C118552586 @default.
- W2980528064 hasConceptScore W2980528064C126322002 @default.
- W2980528064 hasConceptScore W2980528064C15744967 @default.
- W2980528064 hasConceptScore W2980528064C169760540 @default.
- W2980528064 hasConceptScore W2980528064C2776991684 @default.
- W2980528064 hasConceptScore W2980528064C2777332695 @default.
- W2980528064 hasConceptScore W2980528064C2778186239 @default.
- W2980528064 hasConceptScore W2980528064C2779965356 @default.
- W2980528064 hasConceptScore W2980528064C2780876210 @default.
- W2980528064 hasConceptScore W2980528064C34628245 @default.
- W2980528064 hasConceptScore W2980528064C529278444 @default.
- W2980528064 hasConceptScore W2980528064C57236427 @default.
- W2980528064 hasConceptScore W2980528064C71924100 @default.
- W2980528064 hasConceptScore W2980528064C98274493 @default.
- W2980528064 hasFunder F4320321001 @default.
- W2980528064 hasFunder F4320323068 @default.
- W2980528064 hasFunder F4320327223 @default.
- W2980528064 hasIssue "3" @default.
- W2980528064 hasLocation W29805280641 @default.
- W2980528064 hasOpenAccess W2980528064 @default.
- W2980528064 hasPrimaryLocation W29805280641 @default.
- W2980528064 hasRelatedWork W2035384001 @default.
- W2980528064 hasRelatedWork W2054707860 @default.
- W2980528064 hasRelatedWork W2063228636 @default.
- W2980528064 hasRelatedWork W2066046553 @default.
- W2980528064 hasRelatedWork W2137295895 @default.
- W2980528064 hasRelatedWork W2139182179 @default.
- W2980528064 hasRelatedWork W2167613432 @default.
- W2980528064 hasRelatedWork W2521785228 @default.
- W2980528064 hasRelatedWork W2980528064 @default.
- W2980528064 hasRelatedWork W3201969094 @default.
- W2980528064 hasVolume "21" @default.
- W2980528064 isParatext "false" @default.
- W2980528064 isRetracted "false" @default.
- W2980528064 magId "2980528064" @default.
- W2980528064 workType "article" @default.